HTGF and TGFS invest in denovoMATRIX

High-Tech Gründerfonds and Technologiegründerfonds Sachsen invest in denovoMATRIX‘ vision of enabling human biology in vitro.

Dr. Fabian Mohr, Investment Manager at HTGF: “In order to be able to offer high-quality stem cell therapies in the future, manufacturers must keep their variability in cell cultivation low. denovoMATRIX products offer a chemically defined solution to this problem, which we hope will provide a good basis for the translation of stem cell therapies from research into clinical practice.

Take a look at the press release from High-Tech Gründerfonds (ENG) and the article of Technologiegründerfonds Sachsen (GER) for more information.

2018-12-11T15:51:51+02:000 Comments

Leave A Comment

We use cookies on different pages in order to make our website more attractive to visitors. By using this website, you consent to the use of cookies in accordance with our privacy policy. Got it